PRMT1 and neoplasm: In a recent study, PRMT1 inhibitor and the PD-1 antibody has been reported to be effective in suppressing B16-derived xenograft syngeneic mouse model54, indicating that this combined immunotherapy might be a valid option for tumor with either higher or low immunogenicity.